Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today

Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, describes what maintenance regimens are being used for multiple myeloma patients today and if that will change as a result of the clinical presentations at ASH

Published: 13 December 2018

Recent Videos

video

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, outlines the role ...

video

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about reliable ...

video

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, offers opinion on ...

video

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, considers the role of ...

video

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, shares what physicians ...

video

David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on the effectiveness of ...

video

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, considers how combined ...

video

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on how pembrolizumab compares ...

video

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA, considers the ...

video

David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about the ...

Related Videos

video-image

Robert Figlin, MD and Richard Finn, MD, Discuss Clinical Highlights from ASCO GI 2019

video-image

Robert Figlin, MD and Tanios Bekaii-Saab, MD, FACP, Discuss Clinical Highlights from ASCO GI 2019

video-image

Robert Figlin, MD and Frederick Locke, MD, Discuss CAR-T Highlights from ASH 2018

video-image

Robert Figlin, MD and Sagar Lonial, MD, Discuss Multiple Myeloma Highlights from ASH 2018

video-image

Robert Figlin, MD and Debu Tripathy, MD, Discuss Breast Cancer Highlights from ESMO 2018

video-image

David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

video-image

Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma

video-image

Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma

video-image

Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

video-image

Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer

video-image

David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC